Literature DB >> 12471622

Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.

Jörgen Bierau1, Albert H Van Gennip, René Leen, Jozien Helleman, Huib N Caron, André B P Van Kuilenburg.   

Abstract

CPEC is a potent inhibitor of CTP synthetase and causes depletion of CTP and dCTP pools. AraC is an analog of dCyd and a chemotherapeutic agent. Here, we demonstrate that, upon incubation with CPEC, both the anabolism and cytostatic effect of AraC in SK-N-BE(2)c neuroblastoma cells were increased. Cotreatment of CPEC (50-250 nM) and AraC (37.5-500 nM) decreased the 4-day ED(50) value for AraC 2- to 8-fold in the SK-N-BE(2)c cell line, while pretreatment with CPEC followed by incubation with AraC alone decreased the 4-day ED(50) value for AraC 1- to 19-fold. Preincubation of SK-N-BE(2)c cells with 100 nM CPEC followed by incubation with 500 nM [(3)H]AraC increased the total amount of AraC nucleotides and incorporation of [(3)H]AraC into DNA by 392% and 337%, respectively, compared to non-CPEC-treated cells. When 20 nM [(3)H]AraC was used, the maximum incorporation of [(3)H]AraC into DNA was 1,378% compared to non-CPEC-treated cells. Incorporation of AraC into DNA correlated well with the accumulation of cells in S phase of the cell cycle caused by CPEC. DNA synthesis was almost completely inhibited (>91%) when 100 nM CPEC and 500 nM AraC were combined. CPEC alone and the combination of CPEC and AraC increased caspase-3 activity 3-fold, indicating induction of apoptosis in SK-N-BE(2)c cells. In contrast, AraC alone did not induce caspase-3 activity. Our results demonstrate that low concentrations of CPEC profoundly increase the cytostatic properties of AraC toward SK-N-BE(2)c human neuroblastoma cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12471622     DOI: 10.1002/ijc.10858

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Mechanisms of product feedback regulation and drug resistance in cytidine triphosphate synthetases from the structure of a CTP-inhibited complex.

Authors:  James A Endrizzi; Hanseong Kim; Paul M Anderson; Enoch P Baldwin
Journal:  Biochemistry       Date:  2005-10-18       Impact factor: 3.162

Review 2.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

Review 3.  New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2009-01-23       Impact factor: 12.310

4.  Crystal structure of Escherichia coli cytidine triphosphate synthetase, a nucleotide-regulated glutamine amidotransferase/ATP-dependent amidoligase fusion protein and homologue of anticancer and antiparasitic drug targets.

Authors:  James A Endrizzi; Hanseong Kim; Paul M Anderson; Enoch P Baldwin
Journal:  Biochemistry       Date:  2004-06-01       Impact factor: 3.162

5.  Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.

Authors:  C van Bree; Hm Rodermond; R Leen; Jp Medema; Abp van Kuilenburg
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

Review 6.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

7.  Structural basis for isoform-specific inhibition of human CTPS1.

Authors:  Eric M Lynch; Michael A DiMattia; Steven Albanese; Gydo C P van Zundert; Jesse M Hansen; Joel D Quispe; Madison A Kennedy; Andreas Verras; Kenneth Borrelli; Angela V Toms; Neelu Kaila; Kevin D Kreutter; Joshua J McElwee; Justin M Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.